Wasatch Advisors Inc Selecta Biosciences Inc Transaction History

Wasatch Advisors Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$1.64 - $3.42 $3.39 Million - $7.08 Million	-2,069,757 Closed	0 $0
Q3 2020 Nov 10, 2020	SELL	$2.18 - $2.84 $807,254 - $1.05 Million	-370,300 Reduced 15.18%	2,069,757 $5.13 Million
Q2 2020 Aug 12, 2020	SELL	$1.83 - $4.06 $1.43 Million - $3.18 Million	-783,545 Reduced 24.31%	2,440,057 $6.93 Million
Q1 2020 May 08, 2020	SELL	$1.5 - $4.52 $1.79 Million - $5.39 Million	-1,193,225 Reduced 27.02%	3,223,602 $7.77 Million
Q4 2019 Feb 13, 2020	BUY	$1.32 - $2.47 $3.03 Million - $5.68 Million	2,298,851 Added 108.54%	4,416,827 $10.5 Million
Q3 2019 Nov 14, 2019	SELL	$1.6 - $2.08 $692,891 - $900,758	-433,057 Reduced 16.98%	2,117,976 $3.71 Million
Q2 2019 Aug 07, 2019	SELL	$1.79 - $3.05 $667,077 - $1.14 Million	-372,669 Reduced 12.75%	2,551,033 $0
Q1 2019 May 08, 2019	BUY	$1.47 - $3.06 $4.14 Million - $8.61 Million	2,813,212 Added 2546.12%	2,923,702 $0
Q4 2018 Feb 14, 2019	SELL	$2.66 - $15.93 $322,503 - $1.93 Million	-121,242 Reduced 52.32%	110,490 $293,000
Q3 2018 Nov 07, 2018	SELL	$12.07 - $16.0 $46,988 - $62,288	-3,893 Reduced 1.65%	231,732 $0
Q2 2018 Aug 02, 2018	BUY	$9.36 - $13.25 $185,356 - $262,389	19,803 Added 9.18%	235,625 $0
Q1 2018 May 02, 2018	SELL	$8.49 - $11.82 $261,458 - $364,008	-30,796 Reduced 12.49%	215,822 $0
Q4 2017 Jan 16, 2018	BUY	$8.97 - $23.38 $1.11 Million - $2.89 Million	123,695 Added 100.63%	246,618 $0
Q3 2017 Nov 08, 2017	SELL	$15.22 - $20.03 $22,358 - $29,424	-1,469 Reduced 1.18%	122,923 $0
Q2 2017 Aug 16, 2017	BUY	N/A	124,392	124,392 $0

4.67M

Ticker SELB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 152,712,992
Market Cap $128M
Description
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia. I...

Get notified when there are updates to the investment portfolio of Wasatch Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Wasatch Advisors Inc with notifications on news.